Status:
UNKNOWN
Effects of Omega-3 Fish Oil Fat Emulsion on Rehabilitation and Immune Function After Radical Surgery Combined With Intraperitoneal Hyperthermic Infusion Chemotherapy in Patients With Locally Advanced Gastric Cancer
Lead Sponsor:
The Affiliated Hospital of Qingdao University
Conditions:
Fish Oils
Perfusion; Complications
Eligibility:
All Genders
18-75 years
Brief Summary
The purpose of this study was to investigate the effects of omega-3 fish oil fat emulsion on peripheral blood C-reactive protein, total lymphocyte count, plasma albumin and immune function after radic...
Detailed Description
The research process is as follows: 1. Select patients in the group according to the inclusion and exclusion criteria. 2. The patient signed the informed consent form 3. His system was used to collec...
Eligibility Criteria
Inclusion
- The age is 18 to 75 years old.
- For advanced gastric cancer, according to the TNM staging specified by the 8th edition AJCC, the clinical staging or EUS staging is above T2. There is no distant metastasis before operation, and the tumor does not directly invade the surrounding organs (liver, pancreas, spleen and transverse mesocolon, etc.).
- There is no obvious contraindication to surgery.
- The preoperative physical status score of Eastern American Cancer Cooperation (ECOG) was 0 or 1.
- The preoperative ASA grade was grade Ⅰ-Ⅲ.
- No previous history of gastric surgery, no history of other malignant tumors.
- After explaining the nature and purpose of the study, agree to sign an informed consent form, give voluntary consent to participate in the study, and comply with the requirements of the study.
Exclusion
- Radiotherapy or chemotherapy before operation.
- Use of immunosuppressants such as hormones within 3 months before treatment.
- Preoperative anemia (hemoglobin \< 90g/L) and severe hypoalbuminemia (albumin \< 30g/L).
- With severe heart and lung and other important organ dysfunction.
- More serious metabolic and immune diseases, such as hyperthyroidism, poor blood glucose control in diabetes, obesity, hyperlipidemia (triglyceride \> 3mmol/L, total bile solid \> 6.2mmol/L).
- Severe infection before operation.
- With complete intestinal obstruction, intestinal perforation and intestinal necrosis.
- During the operation, it was found that radical operation could not be performed or combined organ resection was needed.
- Operation time \> 6 hours, intraoperative bleeding \> 400ml
Key Trial Info
Start Date :
December 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06047158
Start Date
December 1 2022
End Date
December 1 2023
Last Update
September 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ruiqing Liu
Qingdao, Shandong, China, 266003